Following a review of rectal spacer options, Varun Sundaram, MD, offers clinical perspectives on hyaluronic acid spacers for patients with prostate cancer undergoing radiation.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.